Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...
Drug
Sirnaomics Initiates Phase I/II Trial for STP705 in Facial Squamous Cell Carcinoma
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in...
CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China
The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...
ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer
Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...
BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia
Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...
Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...
Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing
China-based Junshi Biosciiences (HKG: 1877, SHA: 688180) has announced that another market approval filing for...
SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China
SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a...
Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention
The Center for Drug Evaluation (CDE) website indicates that Shanghai Belief-Delivery BioMed Co., Ltd’s injectable...
Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical...
I-Mab and AbbVie End CD47 Antibody Trial but Continue Collaboration
China-based biotech I-Mab (NASDAQ: IMAB) filed with the US Securities and Exchange Commission (SEC) that...
Grand Pharmaceutical’s Carglumic Acid Set for Priority Review by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Grand Pharmaceutical Group Limited’s (HKG:...
Ascletis Pharma’s Gannex Initiates DDI Study for ASC42 in PBC
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly – owned US unit, Gannex, has...
Luye Pharma’s Goserelin Acetate Injectable Accepted for Breast Cancer Review
China-based Luye Pharma Group (HKG: 2186) announced that another market filing for its goserelin acetate...
CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti
The Center for Drug Evaluation (CDE) website indicates that two drugs have been selected for...
Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...
Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC
China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase...
Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment
Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...